Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1621 1627 1654 1658 1671 1674 1676 1799
This examiner grants 75% of resolved cases
Sudhakar Katakam, based in Tech Center 1700 and Art Unit 1621, has 1306 resolved cases. The examiner maintains an allowance rate of 74.7%. The median days to allowance is 911. This timeframe is a key factor for applicants to consider when managing expectations for patent issuance in this unit.
The interview lift of 23.3% indicates a positive correlation between interviews and allowances. This lift suggests that direct engagement is an effective strategy for increasing the probability of success beyond the 74.7% base rate. Practitioners should factor this 23.3% lift into their strategy for the 1306 resolved cases. The 911-day median pendency is a well-defined benchmark for prosecution in Tech Center 1700. These statistics from Art Unit 1621 offer a data-grounded view of the examiner's historical performance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18121499 | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | Non-Final OA | BAYER HEALTHCARE LLC |
| 18259500 | HALF-LIFE EXTENDING MOIETIES AND METHODS OF USING THE SAME | Final Rejection | Eli Lilly and Company |
| 18718838 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17948904 | Compositions and Methods for Treating Multidrug Resistant Bacterial Infection | Non-Final OA | University of Southern California |
| 18559242 | PURIFICATION OF SPECIFIC TRIPEPTIDE BY USE OF ETHERS | Non-Final OA | DSM IP Assets B.V. |
| 18576518 | MULTIPLE DE NOVO DESIGNED PROTEIN BINDING PROTEINS | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 18772735 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF VASCULAR MALFORMATIONS | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18547837 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 17928381 | STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY | Non-Final OA | Yale University |
| 18575429 | CXC CHEMOKINE AGONISTS AND ANTAGONISTS IN COVID-19 DISEASE AND DIAGNOSTIC ASSAYS | Non-Final OA | The Trustees of Indiana University |
| 17625314 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) LIGANDS | Final Rejection | NANYANG TECHNOLOGICAL UNIVERSITY |
| 18249926 | COMPOSITIONS OF ANTI-VIRAL PEPTIDES AND/OR COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | The University of Hong Kong |
| 16791561 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | Final Rejection | Incyte Corporation |
| 17801115 | DIGESTIVE FLUID LEAK PREVENTATIVE MATERIAL AND ORGAN PROTECTIVE MATERIAL AGAINST DIGESTION BY DIGESTIVE FLUID | Non-Final OA | OSAKA UNIVERSITY |
| 18515672 | SYNTHESIS OF A CYCLIC PEPTIDE | Non-Final OA | Janssen Pharmaceutica NV |
| 18011354 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | Non-Final OA | Stealth Biotherapeutics Inc. |
| 18725112 | Application of Polypeptide in Preparation of Product for Preventing or Treating Skin Injury Diseases | Non-Final OA | Sichuan Gooddoctor Panxi Pharmaceutical Co., Ltd. |
| 18619647 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | Non-Final OA | VectivBio AG |
| 18274622 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE | Non-Final OA | VectivBio AG |
| 18040380 | ANTIFUNGAL MATRIX FORMED FROM PEPTIDE HYDROGELS | Final Rejection | GEL4MED, INC. |
| 18279961 | APPLICATION OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 IN PREPARATION OF DRUGS FOR RESISTING MENTAL DISORDERS CAUSED BY EARLY LIFE STRESS | Non-Final OA | SHANGHAI MENTAL HEALTH CENTER (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENTER) |
| 18318869 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | Final Rejection | ScinoPharm Taiwan, Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy